Clinical trials · Washington, D.C., DC
Solid Tumor clinical trials in Washington, D.C.
We’re tracking 274 recruiting solid tumor studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06162221RecruitingPhase 1/Phase 2
Study of RAS inhibitors for advanced RAS-mutated lung cancer
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06669117RecruitingPhase 1/Phase 2
VERT-002 for solid tumors with MET changes
This trial tests a new drug, VERT-002, for people with advanced solid tumors, including non-small cell lung cancer (NSCLC), that have specific changes in the MET gene. It aims to see if the drug can shrink tumors or stop them from growing when other treatments haven't worked or aren't available.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06115642Enrolling by invitationPhase 1
Study of HLX43 for advanced solid tumors
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
Washington D.C., District of ColumbiaAges 18–75 - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05150691RecruitingPhase 1/Phase 2
Early study of an HER2 drug in advanced solid tumors
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Washington D.C., District of ColumbiaAges 18–75 - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Washington D.C., District of ColumbiaAges 1–21 - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07335497RecruitingPhase 1/Phase 2
Experimental drug CR-001 for advanced solid tumors
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06384807RecruitingPhase 1/Phase 2
Study of BHV-1510 for advanced solid tumors
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT00736749Recruiting
Long-term health check for childhood cancer survivors
This trial tracks the long-term health of people who took part in previous Children's Oncology Group studies. It helps doctors understand the lasting effects of cancer treatment and improve care for survivors.
Washington D.C., District of ColumbiaAges Any age - NCT05868629Recruiting
Test of two targeted drugs for tumors with BRAF V600E
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
Washington D.C., District of ColumbiaAges 1–100 - NCT05661201RecruitingPhase 1
Testing a KRAS drug and doxorubicin for certain solid tumors
This Phase 1 study tests a drug called NEROFE together with doxorubicin in people whose tumors have a specific KRAS mutation and show ST2 in tumor tissue. It’s meant to find the safest dose and whether the treatment can shrink or control these advanced cancers.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07127874RecruitingPhase 1
Study of PHN-012 for advanced solid tumors
This trial tests a new drug called PHN-012 for people with advanced colorectal, non-small cell lung, or pancreatic cancer who have already tried at least one standard treatment. The goal is to see if the drug can help shrink or slow tumor growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Washington D.C., District of ColumbiaAges 18 years+ - NCT01109394Recruiting
Help study tumors with sample testing and a research biology library
This study collects tumor (or related) samples to analyze their genes and build a shared research “biobank.” It may help researchers understand cancers better for future diagnosis and treatments.
Washington D.C., District of ColumbiaAges 4 weeks+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
Washington D.C., District of ColumbiaAges 6 months–25 years - NCT05901285RecruitingPhase 1
Vaccine injected into tumors plus immunotherapy for advanced cancers
This Phase 1 trial tests a cancer vaccine (VAX014) injected directly into a tumor, given alone at first and then with an immune checkpoint medicine (nivolumab or pembrolizumab). It aims to see how well this approach is tolerated and may help shrink advanced solid tumors after other treatments stopped working.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04389281RecruitingPhase 1
X-ray light-activated therapy for hard-to-treat skin tumors
This early-phase study tests an X-ray–activated medicine that is delivered directly into selected tumors to help control cancer that has not responded to standard treatments. If the injected area can be treated safely, it may shrink or slow the tumor and improve local control.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new Solid Tumor trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Solid Tumor trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting solid tumor studies listed above.
- Children's National Medical Center · 4 studies
- Johns Hopkins University · 4 studies
- NEXT Virginia · 3 studies
- Sibley Memorial Hospital · 3 studies
- Georgetown Lombardi Comprehensive Cancer Center · 2 studies
- Georgetown University Medical Center · 2 studies
- Johns Hopkins Sibley Memorial Hospital · 2 studies
- MedStar Georgetown University Hospital · 2 studies
What taking part in a solid tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting solid tumor studies in District of Columbia.
Common questions
- Are there solid tumor clinical trials near Washington, D.C.?
- Yes. We're currently tracking 274 recruiting solid tumor studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a solid tumor study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New solid tumor studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.